ReviewBioengineering & translational medicine2018
How will the field of gene therapy survive its success?
Review in Bioengineering & translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Systems biology in the era of AI: "winter" or "evolution"?Frontiers in systems biology · 2026Article
- Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.Journal of nanobiotechnology · 2023Review
- Viral Vector-Based Gene Therapy.International journal of molecular sciences · 2023Review
- Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Cancer gene therapy goes viral: viral vector platforms come of age.Radiology and oncology · 2022Article
- Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells.FEBS open bio · 2022Article
- Functional Non-coding RNA During Embryonic Myogenesis and Postnatal Muscle Development and Disease.Frontiers in cell and developmental biology · 2021Review
- Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion.Applied microbiology and biotechnology · 2020Article
- Engineering adeno-associated virus vectors for gene therapy.Nature reviews. Genetics · 2020Review
- Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans.Frontiers in neural circuits · 2020Review
- The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.Frontiers in microbiology · 2020Review
- Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease.Frontiers in genetics · 2020Review
- Lysyl Oxidase-Like 2 Protects against Progressive and Aging Related Knee Joint Osteoarthritis in Mice.International journal of molecular sciences · 2019Article
- Editorial: The launch phase ofBioengineering & translational medicine · 2019Article
- Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.Advanced drug delivery reviews · 2019Review
- The Pathway from Gene Therapy to Genome Editing: A Nightmare or Dream.International journal of molecular and cellular medicine · 2019Article
- Circular RNAs in Muscle Function and Disease.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In August 2017, for the first time, a gene therapy was approved for market release in the United States. That approval was followed by two others before the end of the year. This article cites primary literature, review articles concerning particular biotechnologies, and press releases by the FDA and others in order to provide an overview of the current status of the field of gene therapy with respect to its translation into practice. Technical hurdles that have been overcome in the past decades are summarized, as are hurdles that need to be the subject of continued research. Then, some social and practical challenges are identified that must be overcome if the field of gene therapy, having survived past failures, is to achieve not only technical and clinical but also market success. One of these, the need for an expanded capacity for the manufacturing of viral vectors to be able to meet the needs of additional gene therapies that will be coming soon, is a challenge that the talents of current and future bioengineers may help address.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.